*Corresponding author:
Xin Zhai, Shenyang Pharmaceutical University, Shenyang 110016, PR China, China*Corresponding author:
Dajun Zhang, Shenyang Medical College, Shenyang 110034, PR China, ChinaReceived: July 25, 2018; Published: July 30, 2018
DOI: 10.26717/BJSTR.2018.07.001496
To view the Full Article Peer-reviewed Article PDF
Autotaxin (ATX) is a secreted enzyme which hydrolyzes lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA) and choline. The ATX-LPA axis has attracted increasing interest recently for both ATX and LPA are involved in various pathological conditions such as tumor progression and metastasis, fibrotic diseases, arthritis, autoimmune diseases and obesity. Thus, great efforts have been devoted in identifying synthetic ATX inhibitors as new agents for treating various diseases including cancer and fibrotic diseases. Herein, this mini review mainly focused on the binding modes of the reported ATX inhibitors and their indications correspondingly.
Keywords: ATX; ATX-LPA Axis; ATX Inhibitors; Binding Mode; Indications
Keywords: ENPPs: Ectonucleotide Pyrophosphatases/Phosphodiesterases; lysoPLD: Lysophospholipase D; SMB: Somatomedin B; PDE: Phosphodiesterase; NUC: Nuclease; Thr210: Threonine Residue; IPF: Idiopathic Pulmonary Fibrosis
Abstract | Introduction | Binding Modes of Reported ATX Inhibitors | The Main Indications of ATX Inhibitors | Perspective | Acknowledgments | References |